Glenmark Q1: revenue +23% YoY, consolidated PAT ₹483 Cr on a clean, exceptional-free quarter

Glenmark's Q1 FY27 (consolidated, the primary basis) delivered revenue from operations of ₹4,018 Cr, up 23.1% YoY (from ₹3,264 Cr) and 6.6% QoQ, with net profit attributable to owners of ₹483 Cr versus just ₹47 Cr a year ago and ₹301 Cr in the March quarter. The headline PAT jump of ~928% YoY is almost entirely a base effect: the year-ago June quarter absorbed a ₹323 Cr exceptional charge (US generic-drug antitrust settlement provision), whereas this quarter carries no exceptional item at all on a consolidated basis. Adjusting both sides for one-offs, underlying growth is ~+30% in PAT and +53.6% in pre-exceptional PBT (₹643 Cr vs ₹419 Cr) — genuinely strong, but nowhere near the reported multiple. The operating story is margin recovery: net margin expanded to ~12.0% from 7.6% in Q4 and 1.4% a year ago, and EBITDA margin ran near ~20%, helped by lower cost of materials consumed (₹601 Cr vs ₹732 Cr YoY) even as employee costs rose to ₹935 Cr. A note on basis: standalone PAT of ₹736 Cr (EPS ₹26.07) looks far punchier than consolidated ₹483 Cr, but the gap is an accounting artifact — standalone booked a ₹223 Cr exceptional gain on selling its Nebulizer brand portfolio to a wholly-owned subsidiary, which washes out on consolidation. Consolidated is the clean read; readers seeing the ₹736 Cr standalone figure elsewhere should not treat it as the group result. Against management's own framing, the print tracks its June-2026 FY27 guidance of ₹17,000–18,000 Cr revenue and 21–22% EBITDA margin — Q1's ₹4,018 Cr annualises toward the lower end, normal for a seasonally soft first quarter, and confirms the confident tone from the Feb concall (which anchored on US respiratory approvals and margin expansion). The quarter also saw concrete US traction cited in the prior outlook: RYALTRIS nasal spray won US pediatric approval (Jul 21), and Glenmark's US arm launched Sugammadex (a ~$1.6B market, Jul 28) and Olanzapine injection (Jul 6). The one blemish is 6 USFDA observations at the Goa facility (Jun 30), a compliance watch-item given how much of the growth thesis rides on US launches. No specific Street quarterly consensus was published ahead of the print; the read is against full-year guidance rather than a poll estimate.